Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis - European Medical Journal

Continue

Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis

Dermatology

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now